/
This competition and competition with approved therapies will reduce the number and types of patients available for clinical trials involving our product candidates, because some patients who might have opted to enroll in our trials may instead opt to pursue a treatment regimen using an approved therapy or enroll in a trial conducted by one of our competitors. Because the number of qualified cl…
ROIC dropped from -25.25% to -44.57%, capital efficiency is deteriorating. Negative free cash flow of -$914M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
-$1.37B
▼ -88.5% YoY
Op. Margin
—
ROIC
-60.87%
▼ -19.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$1.07B
▼ -60.9% YoY
Op. Cash Flow (TTM)
-$1.06B
▼ -61.0% YoY
Net Debt
-$1.75B
Net Cash Position
Cash & Equiv.
$1.91B
Continue Research